POLE and neoplasm: We assembled a public discovery cohort of 815 patients (1,195 WSIs) from The Cancer Genome Atlas and Clinical Proteomic Tumor Analysis Consortium, and an independent external cohort of 720 patients (1,357 WSIs) with molecular subtyping determined by mismatch repair immunohistochemistry plus TP53 and POLE sequencing.